Pentaglobin Use In Pregnancy & Lactation

Pregnancy: The safety of this medicinal product for use in human pregnancy has not been established in controlled clinical trials and therefore should only be given with caution to pregnant women and breast-feeding mothers. Intravenously administered IgG has been shown to cross the placenta, increasingly during the third trimester. Pentaglobin also contains IgA and IgM. Maternal IgA has been shown to cross the placenta to a lesser extent than IgG. Usually IgM does not cross the placenta in relevant amounts. This may change in case of ascending infections of the birth canal, where transplacental transfer of all three classes of immunoglobulins increases with increasing degree of infection. Clinical experience with immunoglobulins suggests that no harmful effects on the course of pregnancy, or on the foetus and the neonate are expected.
Breastfeeding: Immunoglobulins are excreted into human milk. No negative effects on the breastfed newborns/infants are anticipated.
Fertility: Clinical experience with immunoglobulins suggests that no harmful effects on fertility are to be expected.